Experience With the Priority Review Voucher Program for Drug Development

被引：31
作者：
Kesselheim, Aaron S. [1 ]
Maggs, Lara R. [1 ]
Sarpatwari, Ameet [1 ]
机构：
[1] Harvard Univ, Program Regulat Therapeut & Law PORTAL, Sch Med, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02120 USA
来源：
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2015年 / 314卷 / 16期
关键词：
D O I：
10.1001/jama.2015.11845
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1687 / 1688
页数：2
相关论文
共 5 条
[1]   Novartis under fire for accepting new reward for old drug [J].
Anderson, Tatum .
LANCET, 2009, 373 (9673) :1414-1414
[2]   Approval of a Tuberculosis Drug Based on a Paradoxical Surrogate Measure [J].
Avorn, Jerry .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2013, 309 (13) :1349-1350
[3]   DRUGS FOR NEGLECTED DISEASES US incentive scheme for neglected diseases: a good idea gone wrong? [J].
Doshi, Peter .
BMJ-BRITISH MEDICAL JOURNAL, 2014, 349
[4]  
Pecoul B, PLOS BLOGS
[5]  
Philippidis A., 2014, GENETIC ENG BIO 0304
1